Upgrade to SI Premium - Free Trial

Dianthus Therapeutics (DNTH)

102.76 -2.96 (2.80%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form 4 Dianthus Therapeutics, For: Jul 09 Filed by: Savitz Ryan July 13, 2026 5:00 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan July 9, 2026 4:27 PM - SEC Filing Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) July 2, 2026 4:01 PM - Globe NewsWire Dianthus starts Phase 3 trial of claseprubart in myasthenia gravis June 29, 2026 7:01 AM - StreetInsider Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis June 29, 2026 7:00 AM - Globe NewsWire Form 4 Dianthus Therapeutics, For: Jun 17 Filed by: Veness Adam M June 18, 2026 4:30 PM - SEC Filing Form 144 Dianthus Therapeutics, Filed by: Veness Adam M June 17, 2026 4:33 PM - SEC Filing Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)' June 12, 2026 2:53 PM - StreetInsider Form 8-K Dianthus Therapeutics, For: Jun 12 June 12, 2026 7:01 AM - SEC Filing Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view' June 10, 2026 4:10 PM - StreetInsider Dianthus Therapeutics (DNTH) PT Raised to $132 at Jefferies June 10, 2026 3:52 PM - StreetInsider TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity' June 10, 2026 1:37 PM - StreetInsider Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart' June 10, 2026 1:01 PM - StreetInsider Wolfe Research on Dianthus Therapeutics (DNTH): 'Not a negative but also not a strong positive' June 10, 2026 10:40 AM - StreetInsider Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited' June 10, 2026 10:38 AM - StreetInsider Dianthus Therapeutics (DNTH) Reiterated at Buy by Stifel June 10, 2026 7:21 AM - StreetInsider Form 4 Dianthus Therapeutics, For: Jun 01 Filed by: Randhawa Simrat June 2, 2026 7:00 PM - SEC Filing Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 2, 2026 4:01 PM - Globe NewsWire Form 144 Dianthus Therapeutics, Filed by: Randhawa Simrat June 1, 2026 4:14 PM - SEC Filing Dianthus Therapeutics to Participate in Two Investor Conferences May 26, 2026 4:01 PM - Globe NewsWire Form 4 Dianthus Therapeutics, For: May 21 Filed by: Romano Steven J. May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: McGeorge Anne May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: Read Simon May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: Lawton Alison Frances May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: Violin Jonathan May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: KANGO SUJAY May 22, 2026 4:30 PM - SEC Filing Form 4 Dianthus Therapeutics, For: May 21 Filed by: Soteropoulos Paula May 22, 2026 4:30 PM - SEC Filing Form 8-K Dianthus Therapeutics, For: May 21 May 22, 2026 4:10 PM - SEC Filing Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases May 19, 2026 3:00 PM - Globe NewsWire Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P. May 15, 2026 4:46 PM - SEC Filing Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Point72 Asset Management, L.P. May 15, 2026 4:34 PM - SEC Filing Form SCHEDULE 13G Dianthus Therapeutics, Filed by: Sirenia Capital Management LP May 15, 2026 8:14 AM - SEC Filing Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP May 15, 2026 7:25 AM - SEC Filing Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Octagon Capital Advisors LP May 14, 2026 4:02 PM - SEC Filing Intellia short interest rises most among biotech stocks in latest period - Baird May 12, 2026 9:58 AM - StreetInsider Form 4 Dianthus Therapeutics, For: May 08 Filed by: Soteropoulos Paula May 11, 2026 5:00 PM - SEC Filing LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis May 5, 2026 10:57 PM - Globe NewsWire Dianthus Therapeutics (DNTH) Misses Q1 EPS by 85c May 5, 2026 5:27 PM - StreetInsider Form 10-Q Dianthus Therapeutics, For: Mar 31 May 5, 2026 4:08 PM - SEC Filing Form 8-K Dianthus Therapeutics, For: May 05 May 5, 2026 4:04 PM - SEC Filing Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results May 5, 2026 4:01 PM - Globe NewsWire Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 1, 2026 4:30 PM - Globe NewsWire Form SCHEDULE 13G Dianthus Therapeutics, Filed by: BlackRock, Inc. April 27, 2026 4:14 PM - SEC Filing Full Article List